Temasek Holdings has expanded its footprint in Asia and Europe through investments and acquisitions.
Accuron Technologies, a technology and engineering holding company wholly owned by Temasek Holdings, has acquired a majority stake in Malaysia-based Aurum Healthcare.
This is the sixth medical technology-related deal for Accuron Medtech Group, a division within Accuron Technologies, in the last 21/2 years.
Announcing the latest deal yesterday, Accuron Technologies said its medtech division was set up to take advantage of opportunities in the global medtech market, which is seen as reaching some US$537 billion (S$722 billion) by 2020.
The Asia-Pacific is the fastest growing region and is forecast to become the second-largest market for medtech at US$133 billion by 2020, said the company.
Accuron Medtech said it will place Aurum under Advanced Materials Technologies (AMT), its Singapore-based contract manufacturing partner.
The acquisition will increase AMT's manufacturing footprint from its current 120,000 sq ft of facilities in Singapore and China, to include Aurum's 20,000 sq ft facility at the Setia Business Park, in Johor Baru.
Temasek Holdings has also invested in French asset manager Tikehau Capital Partners.
It is among a group of investors injecting €510 million (S$763 million) in Tikehau and its holding company, as part of two capital increases, the Paris-based firm said in a statement.
Temasek now holds a stake of more than 5 per cent in the holding company, Tikehau Capital Advisors.
Tikehau manages over €8 billion for institutional and private investors in various asset classes.